A recent meta-analysis of the literature using different studies including diverse patient cohorts concluded that EGFR and Her-2 have a limited influence on patient outcome, although their broad conclusion highlights the fact that studies need to be restricted to specific subtypes of ovarian cancer [11]. The gene discussed is ERBB2; the disease is ovarian cancer.